King Pharmaceuticals KG Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue.
The official record: King Pharmaceuticals’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value?
- King Pharmaceuticals (KG) reported fair value measurement with unobservable inputs reconciliation recurring basis asset value of $144.31M in Q3 2025.